
OPKO Health (OPK) Stock Forecast & Price Target
OPKO Health (OPK) Analyst Ratings
Bulls say
OPKO Health Inc has strategically focused its business on drug development, which is expected to enhance its financial position and strengthen its balance sheet by streamlining operations following recent divestitures. The company reported a total revenue of $183.6 million for Q4 2024, reflecting a year-over-year growth of 0.9%, which surpassed expectations and demonstrates resilience in its financial performance. Additionally, improvements in BioReference's productivity and the management's commitment to achieving profitability by 2025 indicate a positive trajectory for the company's diagnostics segment, further supporting an optimistic outlook for OPKO Health's stock.
Bears say
OPKO Health Inc. reported a significant 17% year-over-year decline in diagnostics services revenue, totaling $103.1 million, largely attributed to reduced clinical test volume after the sale of certain BioReference assets. The company's overall revenue for the full year 2024 also decreased by 17% year-over-year to $713.1 million, with pharmaceutical products revenue falling by 13% to $37.4 million due to unfavorable foreign currency exchange rates. The company faces multiple risks, including slow growth in the diagnostics segment, challenges in developing new pharmaceuticals, and volatility in sales from emerging markets, which contribute to a negative outlook.
This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.
OPKO Health (OPK) Analyst Forecast & Price Prediction
Start investing in OPKO Health (OPK)
Order type
Buy in
Order amount
Est. shares
0 shares